India’s drug regulator has stepped up surveillance on GLP-1 weight loss drugs following a surge in availability after the patent expiry of Semaglutide. With multiple generic versions flooding the mark...
MSME drugmakers flag 200–300% input cost surge, warn of supply risks
Entry of multiple generic versions raises concerns over unauthorised sales
Prices of critical plastics have risen by nearly 50%, while packaging costs and diesel-based power expenses have increased by over 20%, show estimates
Dr. Reddy’s Laboratories is looking to scale its presence in semaglutide as the market opened up following patent expiry, with plans to expand both in India and globally. M V Ramana, CEO – Branded Mar...
Jaime Vallés, VP of Amazon and MD of AWS Global Sales for Asia Pacific, Japan and Greater China, on AI adoption and the tech behemoth's plans in India.
A drug that cost over Rs 10,000 a month is now available for as little as Rs 220 a shot. Multiple companies have entered the market on Day 1 with different prices, formats and strategies, competing fo...
The next generation of weight loss drugs is already in trials. Lilly's retatrutide delivered nearly 17% weight loss in 40 weeks, with patients still losing weight at the end of the trial.
Novo Nordisk India chief says GLP-1 adoption remains low and the market untapped despite patent expiry opening it to generics
Semaglutide went off patent in India on March 20, immediately drawing in generic manufacturers with prices starting as low as Rs 220 a shot. A day earlier, Novo Nordisk had secured US FDA approval for...
PM Modi-Trump Call On West Asia War; Ambassador Sergio Gor Backs India On Crucial Hormuz Stand
War Hits Mumbai: Dabbawalas Slow Down As Gas Crisis Breaks 150-Year Lifeline
IPL Champions RCB Sold To Aditya Birla Group-Led Consortium For Rs 16,660 Crore
Trump Flips On Iran Talks; Pakistan’s Surprise Power Play Shakes Global Diplomacy
RS 160 Crore FD Scam In Haryana: Kotak Mahindra Bank Officials Accused In Panchkula Fraud
